Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anne Wallart Brejaud"'
Autor:
Maxime Berquier, Lucie Cherel, Dominique Clerc Renaud, Carole Hospital Gustems, Anne Wallart Brejaud, Ibrahim Yakoub-Agha, David Beauvais
Publikováno v:
Bulletin du Cancer. 108:S39-S44
In the attempt to harmonize practices and to create a national CAR T-cells patient follow-up care logbook, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) worked on the design of a common national care logbook du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d244f8f46b6ca7f19441c09f45780cc
https://doi.org/10.1016/j.bulcan.2021.02.012
https://doi.org/10.1016/j.bulcan.2021.02.012
Autor:
Ibrahim Yakoub-Agha, Anne Wallart Brejaud, Isabelle Fournier, Christelle Andrianne, Corinne Courbon, Josiane Delorme, Sarah Bole, Clotilde Aubrun, Maxime Berquier, Damien Lacroix, Ghislaine François, David Beauvais, Marlene Vercasson, Marie-France Jaivenois, Isabelle Mussot, Alexis Caulier, Laetitia Le Bars
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2020, 107, pp.S170-S177. ⟨10.1016/j.bulcan.2020.05.014⟩
Bulletin du Cancer, 2020, 107, pp.S170-S177. ⟨10.1016/j.bulcan.2020.05.014⟩
Bulletin du Cancer, John Libbey Eurotext, 2020, 107, pp.S170-S177. ⟨10.1016/j.bulcan.2020.05.014⟩
Bulletin du Cancer, 2020, 107, pp.S170-S177. ⟨10.1016/j.bulcan.2020.05.014⟩
International audience; In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03db488bc89c986082e1ae6c920d6813
https://hal.archives-ouvertes.fr/hal-03492618
https://hal.archives-ouvertes.fr/hal-03492618
Autor:
Maxime, Berquier, Lucie, Cherel, Dominique, Clerc Renaud, Carole, Hospital Gustems, Anne, Wallart Brejaud, Ibrahim, Yakoub-Agha, David, Beauvais
Publikováno v:
Bulletin du cancer. 108(12S)
In the attempt to harmonize practices and to create a national CAR T-cells patient follow-up care logbook, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) worked on the design of a common national care logbook du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9940ddd3dfa57f3daf3bb3fe5951bae9
https://pubmed.ncbi.nlm.nih.gov/33992416
https://pubmed.ncbi.nlm.nih.gov/33992416
Autor:
David, Beauvais, Christelle, Andrianne, Clotilde, Aubrun, Maxime, Berquier, Sarah, Bole, Alexis, Caulier, Corinne, Courbon, Josiane, Delorme, Isabelle, Fournier, Ghislaine, François, Marie-France, Jaivenois, Laëtitia, Le Bars, Isabelle, Mussot, Marlène, Vercasson, Anne, Wallart Brejaud, Ibrahim, Yakoub-Agha, Damien, Lacroix
Publikováno v:
Bulletin du cancer. 107(12S)
In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantation centers still need to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e61b94787e7da9887d1a4e0c8c8bd5f9
https://pubmed.ncbi.nlm.nih.gov/32891406
https://pubmed.ncbi.nlm.nih.gov/32891406